Evaluation of tumor infiltrating lymphocytes in breast carcinomas

Background: Among the parameters that have a prognostic and/or predictive significance to therapeutic response, in the case of breast carcinoma, the study of tumor-infiltrating lymphocytes in breast carcinomas is emerging. The present study aimed to access the clinicopathological profiles of tumor-i...

Full description

Saved in:
Bibliographic Details
Main Authors: Shovana Karki, Sansar Babu Tiwari, Alina Basnet
Format: Article
Language:English
Published: Association of Clinical Pathologists of Nepal 2022-09-01
Series:Journal of Pathology of Nepal
Online Access:https://www.nepjol.info/index.php/JPN/article/view/47200
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849230254696038400
author Shovana Karki
Sansar Babu Tiwari
Alina Basnet
author_facet Shovana Karki
Sansar Babu Tiwari
Alina Basnet
author_sort Shovana Karki
collection DOAJ
description Background: Among the parameters that have a prognostic and/or predictive significance to therapeutic response, in the case of breast carcinoma, the study of tumor-infiltrating lymphocytes in breast carcinomas is emerging. The present study aimed to access the clinicopathological profiles of tumor-infiltrating lymphocytes in patients with primary breast carcinoma. Materials and Methods: Information was collected from the archive of the Department of Pathology, about invasive breast cancers diagnosed between April 2019 –March 2020. Hormone receptor status and Ki-67 index were assessed. For tumor-infiltrating lymphocytes, hematoxylin and eosin sections were evaluated following the guidelines of the “International Working Group for tumor-infiltrating lymphocytes in Breast Cancer—2014”. Results:  High tumor-infiltrating lymphocytes were seen in 64.2% and 43.8% in ages < 50 and > 50 respectively. All cases of invasive lobular carcinoma had low tumor-infiltrating lymphocytes. 62.5% of T1 tumors were associated with low TILs whereas 80% of low tumor-infiltrating lymphocytes were T3. 71.4% of lymph node-positive tumors had low tumor-infiltrating lymphocytes. All breast cancers showed lymphocytic infiltrate.  40% of the tumors showed intermediate to high tumor-infiltrating lymphocytes.  Lymphocyte-predominant breast cancers were 30%. Among the LPBC, 55.5% were triple-negative breast cancers, 33.3% were HR+, and 11.2% were HER2 positive. Conclusions: Low tumor-infiltrating lymphocytes presented at an advanced stage of the disease at the time of diagnosis. tumor-infiltrating lymphocytes in breasts decreased with increasing age. LPBCs were predominantly TNBCs. All breast cancers were immunogenic, stating the necessity to report tumor-infiltrating lymphocytes in all breast carcinomas.
format Article
id doaj-art-b9f2c2b7d915401bbe151066f06508be
institution Kabale University
issn 2091-0797
2091-0908
language English
publishDate 2022-09-01
publisher Association of Clinical Pathologists of Nepal
record_format Article
series Journal of Pathology of Nepal
spelling doaj-art-b9f2c2b7d915401bbe151066f06508be2025-08-21T07:03:01ZengAssociation of Clinical Pathologists of NepalJournal of Pathology of Nepal2091-07972091-09082022-09-011221909191210.3126/jpn.v12i2.4720074267Evaluation of tumor infiltrating lymphocytes in breast carcinomasShovana Karki0https://orcid.org/0000-0001-5429-2422Sansar Babu Tiwari1https://orcid.org/0000-0001-5429-2422Alina Basnet2https://orcid.org/0000-0001-5429-2422Institute of Medicine, Tribhuvan University Teaching HospitalInstitute of Medicine, Tribhuvan University Teaching HospitalInstitute of Medicine, Tribhuvan University Teaching HospitalBackground: Among the parameters that have a prognostic and/or predictive significance to therapeutic response, in the case of breast carcinoma, the study of tumor-infiltrating lymphocytes in breast carcinomas is emerging. The present study aimed to access the clinicopathological profiles of tumor-infiltrating lymphocytes in patients with primary breast carcinoma. Materials and Methods: Information was collected from the archive of the Department of Pathology, about invasive breast cancers diagnosed between April 2019 –March 2020. Hormone receptor status and Ki-67 index were assessed. For tumor-infiltrating lymphocytes, hematoxylin and eosin sections were evaluated following the guidelines of the “International Working Group for tumor-infiltrating lymphocytes in Breast Cancer—2014”. Results:  High tumor-infiltrating lymphocytes were seen in 64.2% and 43.8% in ages < 50 and > 50 respectively. All cases of invasive lobular carcinoma had low tumor-infiltrating lymphocytes. 62.5% of T1 tumors were associated with low TILs whereas 80% of low tumor-infiltrating lymphocytes were T3. 71.4% of lymph node-positive tumors had low tumor-infiltrating lymphocytes. All breast cancers showed lymphocytic infiltrate.  40% of the tumors showed intermediate to high tumor-infiltrating lymphocytes.  Lymphocyte-predominant breast cancers were 30%. Among the LPBC, 55.5% were triple-negative breast cancers, 33.3% were HR+, and 11.2% were HER2 positive. Conclusions: Low tumor-infiltrating lymphocytes presented at an advanced stage of the disease at the time of diagnosis. tumor-infiltrating lymphocytes in breasts decreased with increasing age. LPBCs were predominantly TNBCs. All breast cancers were immunogenic, stating the necessity to report tumor-infiltrating lymphocytes in all breast carcinomas.https://www.nepjol.info/index.php/JPN/article/view/47200
spellingShingle Shovana Karki
Sansar Babu Tiwari
Alina Basnet
Evaluation of tumor infiltrating lymphocytes in breast carcinomas
Journal of Pathology of Nepal
title Evaluation of tumor infiltrating lymphocytes in breast carcinomas
title_full Evaluation of tumor infiltrating lymphocytes in breast carcinomas
title_fullStr Evaluation of tumor infiltrating lymphocytes in breast carcinomas
title_full_unstemmed Evaluation of tumor infiltrating lymphocytes in breast carcinomas
title_short Evaluation of tumor infiltrating lymphocytes in breast carcinomas
title_sort evaluation of tumor infiltrating lymphocytes in breast carcinomas
url https://www.nepjol.info/index.php/JPN/article/view/47200
work_keys_str_mv AT shovanakarki evaluationoftumorinfiltratinglymphocytesinbreastcarcinomas
AT sansarbabutiwari evaluationoftumorinfiltratinglymphocytesinbreastcarcinomas
AT alinabasnet evaluationoftumorinfiltratinglymphocytesinbreastcarcinomas